Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusVictoria Atkinson, Michele Del Vecchio, Bettina Ryll et al.|European Journal of Cancer|2022Cited by 30
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.Victoria Atkinson, Michele Del Vecchio, Caroline Robert et al.|Journal of Clinical Oncology|2021Cited by 9
803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus studyJean‐Jacques Grob, Victoria Atkinson, Caroline Dutriaux et al.|Annals of Oncology|2022Cited by 2
1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanomaJohn M. Kirkwood, Mario Mandalà, Reinhard Dummer et al.|Annals of Oncology|2020Cited by 1